About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3665495
Allelic
Composition
Ccr2tm1Blck/Ccr2tm1Blck
Faslpr/Faslpr
Genetic
Background
MRL.Cg-Ccr2tm1Blck Faslpr
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ccr2tm1Blck mutation (3 available); any Ccr2 mutation (43 available)
Faslpr mutation (39 available); any Fas mutation (82 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• life span is considerably reduced on average but considerably longer than Faslpr controls

immune system
• frequency of CD4+ T cells in peripheral blood is significantly reduced relative to Faslpr controls
• percentage of CD8+ T cells is markedly reduced at 14 and 20 weeks of age relative to Faslpr controls
• levels significantly reduced relative to Faslpr controls
• levels significantly reduced relative to Faslpr controls
• enlargement is significantly less at 14 weeks of age than in Faslpr controls
• spleen enlargement at 20 weeks equivalent to controls
• enlargement is significantly less than in Faslpr controls
• less T-cell and macrophage infiltration than in Faslpr controls
• not as extensive as in Faslpr controls

renal/urinary system
• significantly less developed at 8 and 14 weeks but comparable to Faslpr controls at 20 weeks
• less T-cell and macrophage infiltration than in Faslpr controls
• not as extensive as in Faslpr controls
• abnormalities much less than in Faslpr controls
• abnormalities seen at 14 weeks of age include hypercellular glomeruli, increased mesangial matrix, and perivascular lymphoid cell accumulations
• increased mesangial matrix at 14 weeks of age
• intraglomerular necrosis and sclerosis less developed than in Faslpr controls
• tubular damage and atrophy less than in Faslpr controls

hematopoietic system
• enlargement is significantly less at 14 weeks of age than in Faslpr controls
• spleen enlargement at 20 weeks equivalent to controls
• frequency of CD4+ T cells in peripheral blood is significantly reduced relative to Faslpr controls
• percentage of CD8+ T cells is markedly reduced at 14 and 20 weeks of age relative to Faslpr controls

homeostasis/metabolism
• levels significantly reduced relative to Faslpr controls
• levels significantly reduced relative to Faslpr controls
• significantly less developed at 8 and 14 weeks but comparable to Faslpr controls at 20 weeks

growth/size/body
• enlargement is significantly less at 14 weeks of age than in Faslpr controls
• spleen enlargement at 20 weeks equivalent to controls


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory